RT Journal
A1 Hampton T
T1 CAncer drug resistance
JF JAMA
JO JAMA
YR 2013
FD January 2
VO 309
IS 1
SP 20
OP 20
DO 10.1001/jama.2012.173440
UL http://dx.doi.org/10.1001/jama.2012.173440
AB 
The researchers identified MED12 when looking for genes that, when suppressed, confer resistance to the targeted therapy crizotinib in non–small cell lung cancer cells. They then found that MED12 inhibition resulted in resistance not only to crizotinib, but also to other targeted drugs and chemotherapy used to treat colon cancer, melanoma, and liver cancer. Previous research has revealed mutations in MED12 in various types of cancer cells.